-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Clinical Care and Research Implications Following Voxelotor Withdrawal

Program: Special-Interest Sessions
Monday, December 9, 2024: 10:30 AM-12:00 PM
Room 33 (San Diego Convention Center)
Chair:
John J Strouse, MD, PhD, Duke University
Disclosures:
No relevant conflicts of interest to declare.
Immediate Fall Out Post-Voxelotor Withdrawal

John J Strouse, MD, PhD

Duke University, Durham, NC
Implications for Ongoing Clinical Research in SCD and Drug Development

Maureen Okam Achebe, MD, MPH

Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Landscape of SCD Treatment Options and New Therapies

Alexis Thompson, MD, MPH

Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
See more of: Special-Interest Sessions
<< Previous Session | Next Session >>